Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy

International Journal of Cancer

Volumn 111, Issue 3, 2004, Pages 398-403

  Varadhachary, Atul ^a   Wolf, Jeffrey S ^b   Petrak, Karel ^a   O'Malley Jr , Bert W ^c   Spadaro, Michela ^d   Curcio, Claudia ^d   Forni, Guido ^d   Pericle, Federica ^a  

^a AGENNIX INC   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

IL 18; Immunotherapy; Lactoferrin

Indexed keywords

CISPLATIN; CYTOKINE; IMMUNOMODULATING AGENT; INTERLEUKIN 18; LACTOFERRIN; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOMODULATION; INTESTINE; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LACTOFERRIN; MICE; MICE, INBRED BALB C; MICE, NUDE; RECOMBINANT PROTEINS;

EID: 3242882447     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20271     Document Type: Article

References (31)

1. Kanyshkova TG, Buneva VN, Nevinsky GA. Lactoferrin and its biological functions. Biochemistry 2001;66:1-7.
2. Wright DG, Gallin, JI. Secretory responses of human neutrophils: exocytosis of specific (secondary) granules by human neutrophils during adherence in vitro and during exudation in vivo. J Immunol 1979;123:285-94.
3. Ward PP, Piddington CS, Cunningham GA, Zhou X, Wyatt RD, Conneely OM. A system for production of commercial quantities of human lactoferrin: a broad spectrum natural antibiotic. Biotechnology 1995;13:498-503.
4. Sun XL, Baker HM, Shewry SC, Jameson GB, Baker EN. Structure of recombinant human lactoferrin expressed in Aspergillus awamori. Acta Crystallogr D Biol Crystallogr 1999;55:403-7.
5. Vorland LH. Lactoferrin: a multifunctional glycoprotein. APMIS 1999;107:971-81.
6. Anderson BF, Baker HM, Norris GE, Rumball SV, Baker EN. Apolactoferrin structure demonstrates ligand-induced conformational change in transferrins. Nature 1990;344:784-7.
7. Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M. Antibacterial spectrum of lactoferrin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 1992;73:472-9.
8. Horwitz DA, Bakke AC, Abo W, Nishiya K. Monocyte and NK cell cytotoxic activity in human adherent cell preparations: discriminating effects of interferon and lactoferrin. J Immunol 1984;132:2370-4.
9. Shau H, Kim A, Golub H. Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. J Leukoc Biol 1992;51:343-9.
10. Gahr M, Speer CP, Damerau B, Sawatzki G. Influence of lactoferrin on the function of human polymorphonuclear leukocytes and monocytes. J Leukoc Biol 1991;49:427-33.
11. Baker EN, Baker HM, Kidd RD. Lactoferrin and transferring: functional variation on a common structural framework. Biochem Cell Biol 2002;80:27-34.
12. Togawa J, Nagase H, Tanaka K, Inamori M, Nakajima A, Ueno N, Saito T, Sekihara H. Oral administration of lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. J Gastroenterol Hepatol 2002;17:1291-8.
13. Hanson LA, Mattsby-Baltzer I, Engberg I, Roseanu A, Elverfors J, Motas C. Anti-inflammatory capacities of human milk: lactoferrin and secretory IgA inhibit endotoxin-induced cytokine release. Adv Exp Med Biol 1995;371A:669-72.
14. Bezault J, Bhimani R, Wiprovnick J, Furmanski P. Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res 1994;54:2310-2.
15. Tanaka T, Kawabata K, Kohno H, Honjo S, Murakami M, Ota T, Tsuda H. Chemopreventive effect of bovine lactoferrin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats. Jpn J Cancer Res 2000;91:25-33.
16. Ushida Y, Sekine K, Kuhara T, Takasuka N, Iigo M, Maeda M, Tsuda H. Possible chemopreventive effects of bovine lactoferrin on esophagus and lung carcinogenesis in the rat. Jpn J Cancer Res 1999;90:262-7.
17. Kuhara T. Iigo M, Itoh T, Ushida Y, Sekine K, Terada N, Okamura H. Tsuda H. Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr Cancer 2000;38:192-9.
18. Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E, Spadaro M, Colombo MP, Amici A, Lollini PL, Musiani P, Forni G. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 2003;111:1161-70.
19. Khurana D, Martin EA, Kasperbauer JL, O'Malley BW Jr, Salomao DR, Chen L, Strome SE. Characterization of a spontaneously arising murine squamous cell carcinoma (SCCVII) as a prerequisite for head and neck cancer immunotherapy. Head Neck 2001;23:899-906.
20. Bray D, Yu SZ, Koprowski H 2nd, Rhee J, Kumar S, Pericle F, Suntharalingam M, Van Echo DA, Li D, O'Malley BW Jr. Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2003;129:618-22.
21. Kirken RA, Erwin RA, Taub D, Murphy WJ, Behbod F, Wang L, Pericle F, Farrar WL. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J Leukoc Biol 1999;65:891-9.
22. Hashimoto W, Tanaka F, Robbins PD, Taniguchi M, Okamura H, Lotze MT, Tahara H. Natural killer, but not natural killer T, cells play a necessary role in the promotion of an innate antitumor response induced by IL-18. Int J Cancer 2003;103:508-13.
23. Wang WP, Iigo M, Sato J, Sekine K, Adachi I, Tsuda H. Activation of intestinal mucosal immunity in tumor-bearing mice by lactoferrin. Jpn J Cancer Res 2000;91:1022-7.
24. Biet F, Locht C, Kremer L. Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J Mol Med 2002;80:147-62.
25. Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, Okamura H, Nakanishi K, Akira S. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998;8:383-90.
26. Dao T, Mehal WZ, Crispe IN. IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. J Immunol 1998;161:2217-22.
27. Micallef MJ, Ohtsuki T, Kohno K, Tanabe F, Ushio S, Namba M, Tanimoto T, Torigoe K, Fujii M, Ikeda M, Fukuda S, Kurimoto M. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 1996;26:1647-51.
28. Micallef MJ, Tanimoto T, Kohno K, Ikeda M, Kurimoto M. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res 1997;57:4557-63.
29. Micallef MJ, Yoshida K, Kawai S, Hanaya T, Kohno K, Arai S, Tanimoto T, Torigoe K, Fujii M, Ikeda M, Kurimoto M. In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 1997;43:361-7.
30. Kawakami H, Lonnerdal B. Isolation and function of a receptor for human lactoferrin in human fetal intestinal brush-border membranes. Am J Physiol 1991;261:G841-6.
31. Hu WL, Mazurier J, Sawatzki G, Montreuil J, Spik G. Lactotransferrin receptor of mouse small-intestinal brush border. Binding characteristics of membrane-bound and triton X-100-solubilized forms. Biochem J 1988;249:435-41.